Methods and low dose regimens for treating red blood cell disorders
Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.
1. A method for increasing the percentage of fetal hemoglobin in the blood of a subject, comprising administering to said subject 2,2-dimethylbutyrate as the free acid, a pharmaceutically acceptable salt, or ester thereof;
wherein a total daily dose of 2,2-dimethylbutyrate is more than 10 mg/kg and not more than 40 mg/kg; and wherein after the administration the percentage of fetal hemoglobin in the blood of the subject increases.
2. The method of claim 1 , wherein the 2,2-dimethylbutyrate is administered as sodium 2,2-dimethylbutyrate.
3. The method of claim 1 , wherein said administering is by oral administration.
4. The method of claim 1 , wherein the subject has been diagnosed with a blood disorder or anemia.
5. The method of claim 4 , wherein the blood disorder is a sickle cell disease.
6. The method of claim 4 , wherein the blood disorder is a beta thalassemia.
7. The method of claim 1 , wherein the total daily dose of 2,2-dimethylbutyrate is about 30 mg/kg.
8. The method of claim 1 , wherein the plasma concentration of 2,2-dimethylbutyrate does not exceed a concentration of 170 μg/mL.
9. The method of claim 1 , wherein the amount of fetal hemoglobin in the blood of the subject increases.
10. The method of claim 1 , wherein the amount of total hemoglobin in the blood of the subject increases.
11. The method of claim 1 , wherein said subject is a mammal.
12. The method of claim 11 , wherein said mammal is a human.
13. The method of claim 12 , wherein said human is a child.
14. A method for increasing the percentage of fetal hemoglobin in the blood of a subject comprising administering to said subject:
a) 2,2-dimethylbutyrate as the free acid, a pharmaceutically acceptable salt, or ester thereof, wherein a total daily dose of 2,2-dimethylbutyrate is more than 10 mg/kg and not more than 40 mg/kg; and
b) one or more agents selected from the group consisting of hydroxyurea, decitabine, and an HDAC inhibitor;
wherein after the administration the percentage of fetal hemoglobin in the blood of the subject increases.
15. The method of claim 14 , wherein the subject has been diagnosed with a beta thalassemia.
16. The method of claim 14 , wherein the 2,2-dimethylbutyrate is administered as sodium 2,2-dimethylbutyrate.
17. The method of claim 14 , wherein said administering is by oral administration.
18. The method of claim 14 , wherein the plasma concentration of 2,2-dimethylbutyrate does not exceed a concentration of 170 μg/mL.
19. The method of claim 14 , wherein the amount of fetal hemoglobin in the blood of the subject increases.
20. The method of claim 14 , wherein the amount of total hemoglobin in the blood of the subject increases.
21. The method of claim 1 , further comprising administering to said subject hydroxyurea, decitabine, an HDAC inhibitor, or a combination thereof.
22. The method of claim 14 , wherein the subject has been diagnosed with a blood disorder or anemia.
23. The method of claim 22 , wherein the blood disorder is a sickle cell disease.
24. The method of claim 23 , wherein a total daily dose of 2,2-dimethylbutyrate is about 30 mg/kg day.
25. The method of claim 24 , wherein 2,2-dimethylbutyrate is administered at a dose of about 15 mg/kg twice a day.
26. The method of claim 7 , wherein 2,2-dimethylbutyrate is administered at a dose of about 15 mg/kg twice a day.
27. The method of claim 14 , wherein said subject is a mammal.
28. The method of claim 27 , wherein said mammal is a human.
29. The method of claim 28 , wherein said human is a child.